Summit Partners Public Asset Management LLC Increases Stake in Natera, Inc. (NASDAQ:NTRA)

Summit Partners Public Asset Management LLC boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 3.6% in the third quarter, Holdings Channel.com reports. The fund owned 584,726 shares of the medical research company’s stock after buying an additional 20,521 shares during the quarter. Natera comprises 2.3% of Summit Partners Public Asset Management LLC’s holdings, making the stock its 7th largest holding. Summit Partners Public Asset Management LLC’s holdings in Natera were worth $74,231,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Itau Unibanco Holding S.A. bought a new position in Natera during the 2nd quarter worth approximately $28,000. Quarry LP boosted its position in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after buying an additional 108 shares during the period. Covestor Ltd increased its position in shares of Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares in the last quarter. Finally, Brooklyn Investment Group acquired a new stake in Natera during the 3rd quarter worth $70,000. Institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on NTRA. BTIG Research increased their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Canaccord Genuity Group raised their target price on shares of Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Piper Sandler increased their price objective on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Finally, Leerink Partners upped their target price on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $140.59.

Natera Price Performance

NASDAQ:NTRA opened at $168.45 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The firm has a fifty day simple moving average of $133.88 and a 200 day simple moving average of $119.43. Natera, Inc. has a 1-year low of $53.88 and a 1-year high of $171.95.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.95) EPS. On average, sell-side analysts expect that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Insider Buying and Selling at Natera

In related news, Director Rowan E. Chapman sold 2,614 shares of Natera stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $127.68, for a total transaction of $333,755.52. Following the completion of the sale, the director now owns 7,969 shares of the company’s stock, valued at approximately $1,017,481.92. The trade was a 24.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gail Boxer Marcus sold 9,682 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $159.98, for a total transaction of $1,548,926.36. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at approximately $1,552,445.92. This represents a 49.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 46,503 shares of company stock worth $6,325,804 over the last 90 days. Company insiders own 7.60% of the company’s stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.